FIELD: medicine.
SUBSTANCE: in case of primary tumour size within 1 cm, uterus tumour cells expressing Ki-67, 2 alpha topoisomerase are determined, 2 alpha topoisomerase/Ki-67 correlation coefficient is calculated, and at coefficient value less than or equal to 0.8, favorable outcome without adjuvant therapy is predicted. At coefficient value of more than 0.8, unfavorable course of the disease is predicted, and adjuvant therapy is recommended.
EFFECT: use of the invention allows to improve the accuracy and information content of moderately differentiated endometrioid uterine carcinomas course prediction.
1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING SURVIVAL RATE IN PATIENTS WITH ENDOMETRIOID CANCER OF UTERINE BODY | 2006 |
|
RU2299690C1 |
| METHOD OF PREDICTING RISK OF EARLY RECURRENCE OF ENDOMETRIAL SQUAMOUS CELL CARCINOMA IN PATIENTS WITH STAGE I OF DISEASE | 2023 |
|
RU2812609C1 |
| METHOD FOR PREDICTION OF ENDOMETRIAL CANCER PATIENTS SURVIVAL ON THE BASIS OF THE ESR1 GENE EXPRESSION LEVEL | 2015 |
|
RU2611352C1 |
| TEST-SYSTEM FOR PREDICTION OF RELAPSE DEVELOPMENT IN PATIENTS WITH UTERINE CORPUS CANCER BASED ON EXPRESSION LEVEL OF THE ESR1 GENE | 2017 |
|
RU2661599C1 |
| METHOD FOR PREDICTING THE PROGRESSION OF CERVICAL CANCER IN PATIENTS WITH STAGE IIB | 2022 |
|
RU2789500C1 |
| METHOD FOR PREDICTING THE OUTCOME OF SQUAMOUS CELL CARCINOMA OF THE TONGUE AND OROPHARYNX | 2019 |
|
RU2708786C1 |
| METHOD FOR PREDICTING EARLY RECURRENCE OF CLEAR CELL CARCINOMA OF THE UTERINE BODY | 2022 |
|
RU2784775C1 |
| METHOD FOR PREDICTION OF RECURRENT ENDOMETRIOID OVARIAN CYSTS | 2018 |
|
RU2694882C1 |
| METHOD FOR PREDICTION OF DEVELOPING METASTASES IN UTERINE CANCER PATIENTS BASED ON ANALYSIS OF MAGEA1, MAGEB2 AND PRAME1 GENE EXPRESSION | 2018 |
|
RU2698895C1 |
| METHOD FOR EARLY DIAGNOSIS OF NEOPLASTIC TRANSFORMATION OF ENDOMETRIOID OVARIAN CYSTS | 2020 |
|
RU2730952C1 |
